420 related articles for article (PubMed ID: 21316261)
1. Harnessing dendritic cells to improve allogeneic hematopoietic cell transplantation outcome.
Hashimoto D; Merad M
Semin Immunol; 2011 Feb; 23(1):50-7. PubMed ID: 21316261
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
4. Cytolytic pathways in haematopoietic stem-cell transplantation.
van den Brink MR; Burakoff SJ
Nat Rev Immunol; 2002 Apr; 2(4):273-81. PubMed ID: 12001998
[TBL] [Abstract][Full Text] [Related]
5. Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.
Stelljes M; Specht C; Albring J; Volkmann S; Schlösser V; Pauels HG; Poremba C; Bisping G; Opitz C; Scheffold C; Silling G; Kiehl M; Berdel WE; Kienast J
Transplantation; 2007 Feb; 83(3):314-22. PubMed ID: 17297406
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs for acute graft-versus-host disease.
Khaled Y; Reddy P; Krijanovski O
Expert Opin Emerg Drugs; 2009 Jun; 14(2):219-32. PubMed ID: 19519285
[TBL] [Abstract][Full Text] [Related]
7. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation.
Sangiolo D; Mesiano G; Carnevale-Schianca F; Piacibello W; Aglietta M; Cignetti A
Expert Opin Biol Ther; 2009 Jul; 9(7):831-40. PubMed ID: 19463075
[TBL] [Abstract][Full Text] [Related]
8. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?
Har-Noy M; Slavin S
Med Hypotheses; 2008; 70(6):1186-92. PubMed ID: 18054441
[TBL] [Abstract][Full Text] [Related]
9. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
Michallet M; Dhedin N; Michallet AS
Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
[TBL] [Abstract][Full Text] [Related]
10. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation.
Maury S; Lemoine FM; Hicheri Y; Rosenzwajg M; Badoual C; Cheraï M; Beaumont JL; Azar N; Dhedin N; Sirvent A; Buzyn A; Rubio MT; Vigouroux S; Montagne O; Bories D; Roudot-Thoraval F; Vernant JP; Cordonnier C; Klatzmann D; Cohen JL
Sci Transl Med; 2010 Jul; 2(41):41ra52. PubMed ID: 20650872
[TBL] [Abstract][Full Text] [Related]
11. Progress and prospects: graft-versus-host disease.
Mastaglio S; Stanghellini MT; Bordignon C; Bondanza A; Ciceri F; Bonini C
Gene Ther; 2010 Nov; 17(11):1309-17. PubMed ID: 20508597
[TBL] [Abstract][Full Text] [Related]
12. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
13. Recent progress in allogeneic stem cell transplantation.
Mattsson J
Curr Opin Mol Ther; 2008 Aug; 10(4):343-9. PubMed ID: 18683098
[TBL] [Abstract][Full Text] [Related]
14. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance.
Kline J; Subbiah S; Lazarus HM; van Besien K
Bone Marrow Transplant; 2008 Mar; 41(6):505-13. PubMed ID: 18026144
[TBL] [Abstract][Full Text] [Related]
15. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
Hudecek M; Bartsch K; Tschiedel S; Niederwieser D
Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1511-6. PubMed ID: 18597211
[TBL] [Abstract][Full Text] [Related]
16. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
17. Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease.
Spaapen R; Mutis T
Best Pract Res Clin Haematol; 2008 Sep; 21(3):543-57. PubMed ID: 18790454
[TBL] [Abstract][Full Text] [Related]
18. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Resnick IB; Shapira MY; Slavin S
Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
[TBL] [Abstract][Full Text] [Related]
19. Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation.
Larsen ME; Kornblit B; Larsen MV; Masmas TN; Nielsen M; Thiim M; Garred P; Stryhn A; Lund O; Buus S; Vindelov L
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1370-81. PubMed ID: 20353833
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo selection of recipient-type alloantigen-specific CD4(+)CD25(+) immunoregulatory T cells for the control of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation.
Trenado A; Fisson S; Braunberger E; Klatzmann D; Salomon BL; Cohen JL
Transplantation; 2004 Jan; 77(1 Suppl):S32-4. PubMed ID: 14726768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
